RDHL

RedHill Biopharma Ltd.

The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties RedHill Licenses RHB-102 for...

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate...

RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published RedHill's Talicia Adds 8 Million Lives...

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development Radioprotective Activity of RedHill's...

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court...

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND PR Newswire...

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury RedHill Announces Collaboration with a Leading...